Emirodatamab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) FLT3 tyrosine kinase receptor (Fms-like tyrosine kinase 3; FLT3; FLT-3; CD135; fetal liver kinase-2; FLK2), fused to one that is directed against the CD3 antigen found on T-lymphocytes, with potential immunostimulating and antineoplastic activities. Upon administration, emirodatamab binds to both CD3 on cytotoxic T-lymphocytes (CTLs) and FLT3 found on FLT3-expressing tumor cells. This activates and redirects CTLs to FLT3-expressing tumor cells, which results in the CTL-mediated cell death of FLT3-expressing tumor cells. FLT3, a cytokine receptor belonging to the class III tyrosine kinase receptors, is overexpressed or mutated in most B-lineage and acute myeloid leukemias (AMLs).

**Synonyms:** - AMG 427 - AMG-427 - AMG427 - Anti-FLT3 x Anti-CD3 BiTE AMG 427 - Anti-FLT3/CD3 BiTE Antibody AMG 427 - BiTE Antibody AMG 427 - Bispecific T-cell Engager Antibody AMG 427 - EMIRODATAMAB - FLT3/CD3-directed Bispecific T-cell Engager Antibody AMG 427